These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24503538)

  • 1. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
    Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
    Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
    Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
    Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y
    Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
    Ye YW; Hu S; Shi YQ; Zhang XF; Zhou Y; Zhao CL; Wang GJ; Wen JG; Zong H
    Oncol Rep; 2013 Dec; 30(6):2777-84. PubMed ID: 24126887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
    Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
    Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of fibroblast growth factor 4 in the growth and metastasis of colorectal cancer.
    Ye Y; Jiang D; Li J; Han C; Wang X; Wang F; Li J
    Int J Oncol; 2020 Jun; 56(6):1565-1573. PubMed ID: 32236572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.
    Li J; Ye Y; Wang M; Lu L; Han C; Zhou Y; Zhang J; Yu Z; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 May; 37(5):6881-91. PubMed ID: 26662569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
    Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
    Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.
    Xu M; Chen S; Yang W; Cheng X; Ye Y; Mao J; Wu X; Huang L; Ji J
    Cell Physiol Biochem; 2018; 47(1):151-160. PubMed ID: 29763898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Fibroblast Growth Factor Receptor 4 by Helicobacter pylori via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving SRC Signaling in Gastric Cancer.
    Zhang X; Soutto M; Chen Z; Bhat N; Zhu S; Eissmann MF; Ernst M; Lu H; Peng D; Xu Z; El-Rifai W
    Gastroenterology; 2022 Sep; 163(3):620-636.e9. PubMed ID: 35588797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
    Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
    Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
    Stevenson L; Allen WL; Turkington R; Jithesh PV; Proutski I; Stewart G; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Clin Cancer Res; 2012 Oct; 18(19):5412-26. PubMed ID: 22859720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
    Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
    PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
    Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
    PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
    Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
    J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.
    Fakhr E; Zare F; Azadmanesh K; Teimoori-Toolabi L
    Biomed Pharmacother; 2021 Nov; 143():112091. PubMed ID: 34474344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.